-
Mashup Score: 4James Mock Joins Moderna as Chief Financial Officer - 2 year(s) ago
CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna’s Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the…
Source: investors.modernatx.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron - 2 year(s) ago
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned…
Source: investors.modernatx.comCategories: Hem/Oncs, Latest HeadlinesTweet-
To continue the “Durable Revenue Stream” A new “Booster” to bolster new variants? But give you some antibody titers and no data on clinical outcomes! Utter Pseudoscientific malarkey for 💰 💰 💰 Grab! https://t.co/BDQmg1cplX
-
-
Mashup Score: 33Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5 - 2 year(s) ago
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study Data Being Submitted to Regulators and for Peer Reviewed Publication CAMBRIDGE, MA / ACCESSWIRE / June 22, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its…
Source: investors.modernatx.comCategories: Expert Picks, Latest HeadlinesTweet-
Beyond BA4/BA5 specific boosters promised by Pfizer by October 2022 (likely for vulnerable, older people & many in US will want to boost antibodies to specific variant' T/B cells still working well), the Moderna bivalent vaccine gives high Abs to BA4/5 https://t.co/8r8VeiNqRn
-
-
Mashup Score: 75Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron - 2 year(s) ago
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned…
Source: investors.modernatx.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Moderna releases data on a bivalent booster with both ancestral & Omicron strains. The bivalent vaccine achieved two outcomes: (1) Relative to first vaccine, superior antibody response against Omicron (2) Non-inferior response against ancestral strain ... https://t.co/VCClOXkprN
-
-
Mashup Score: 14Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron - 2 year(s) ago
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned…
Source: investors.modernatx.comCategories: Expert Picks, Latest HeadlinesTweet-
Original Moderna mRNA vaccine to ancestral strain: mRNA 1273 New bivalent vaccine from Moderna with sequences from both ancestral + Omicron variant: mRNA 1273.214 Moderna press release this am says 8-fold increase in neutralizing antibodies w/ mRNA1273.214 https://t.co/o5kBZYZbL2 https://t.co/s1kstuO47l
-
Original Moderna mRNA vaccine to ancestral strain: mRNA 1273 New bivalent vaccine from Moderna with sequences from both ancestral + Omicron variant: mRNA 1273.214 Moderna press release this am: 8-fold increase in neutralizing antibodies with mRNA1273.214 https://t.co/o5kBZYZbL2
-
-
Mashup Score: 4Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron - 2 year(s) ago
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned…
Source: investors.modernatx.comCategories: Expert Picks, Latest HeadlinesTweet-
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against #Omicron https://t.co/LKJ9XpDyDh
-
-
Mashup Score: 1Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron - 2 year(s) ago
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned…
Source: investors.modernatx.comCategories: Latest Headlines, NephrologyTweet-
This is cool Faster please (Moderna Omicron-containing bivalent booster) https://t.co/kW3pxvv6qh
-
-
Mashup Score: 0Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age - 2 year(s) ago
Submission to Regulators Globally Is Based on Phase 2/3 Studies of mRNA-1273 in Young Children CAMBRIDGE, MA / ACCESSWIRE / April 28, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to…
Source: investors.modernatx.comCategories: Cardiologists, Latest HeadlinesTweet-
👀Lower bound of 95% CI < FDA’s 30%: “When the analysis is limited only to cases confirmed positive for SARS-CoV-2 by central lab RT-PCR vaccine efficacy remained significant at 51% (95% CI: 21-69) for 6 months to <2 years and 37% (95% CI: 13-54)” https://t.co/y6dkuZ6C6i
-
-
Mashup Score: 93Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint - 2 year(s) ago
Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this age group Although not a primary endpoint, statistically significant vaccine efficacy was observed during the Omicron wave that was consistent with the lower two-dose effectiveness against Omicron seen…
Source: investors.modernatx.comCategories: Hematologists1, Latest HeadlinesTweet-
RT @EARL_COVID19_tw: モデルナ製新型コロナワクチンの生後6ヶ月〜5歳への接種（成人の1/4量）による感染予防効果は約4割．安全性の懸念はみられなかった．6700例第2/3相治験，KidCOVE試験 https://t.co/yfxOE0mVwQ 有効性・安…
-
-
Mashup Score: 14Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint - 2 year(s) ago
Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this age group Although not a primary endpoint, statistically significant vaccine efficacy was observed during the Omicron wave that was consistent with the lower two-dose effectiveness against Omicron seen…
Source: investors.modernatx.comCategories: Latest Headlines, PayerTweet-
. @moderna_tx says its COVID-19 vaccine phase 2/3 study in children 6 months-5 yrs met primary endpoint. It will seek FDA authorization in the coming weeks. That will be a huge relief to parents of young children. Let's see the data. https://t.co/1TpWScae4Q
-
Likely the most thoroughly vetted CFO in biopharma. $MRNA https://t.co/368jNuBj3O